Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells
- PMID: 16226060
- DOI: 10.1016/j.ymthe.2005.08.012
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells
Abstract
Severe adverse events related to insertional mutagenesis have reinforced interest in self-inactivating (SIN) retroviral vectors lacking enhancer-promoter sequences in the long terminal repeats (LTRs). Here, we have compared the potency of gammaretroviral and lentiviral vectors expressing the P140K mutant of O(6)-methylguanine-DNA methyltransferase (MGMT). MGMT-P140K is a clinically relevant selection marker that mediates a strong survival advantage in hematopoietic cells exposed to alkylating agents. We designed gammaretroviral and lentiviral vectors that contained identical enhancer-promoter sequences located either in the LTR or downstream of the packaging region, for internal initiation of transcription from SIN backbones. Gammaretroviral vectors with intact LTRs containing enhancer-promoter sequences showed both higher titers and higher expression levels than the lentiviral counterparts, likely a result of suboptimal RNA processing of the lentiviral leader region. In the SIN context, gammaretroviral and lentiviral vectors with comparable internal cassettes had similar expression properties. Interestingly, gammaretroviral SIN vectors pseudotyped with RD114/TR had a higher transduction efficiency on proliferating human CD34(+) cells than lentiviral counterparts. These results encourage further investigations into the formation of retroviral hybrid vectors that combine the desired properties of high efficiency and increased biosafety.
Similar articles
-
Mechanisms controlling titer and expression of bidirectional lentiviral and gammaretroviral vectors.Gene Ther. 2010 Mar;17(3):400-11. doi: 10.1038/gt.2009.129. Epub 2009 Oct 22. Gene Ther. 2010. PMID: 19847204
-
A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines.J Gene Med. 2003 Sep;5(9):737-47. doi: 10.1002/jgm.407. J Gene Med. 2003. PMID: 12950064
-
Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.Gene Ther. 2006 Nov;13(21):1524-33. doi: 10.1038/sj.gt.3302807. Epub 2006 Jun 8. Gene Ther. 2006. PMID: 16763662
-
Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.DNA Repair (Amst). 2007 Aug 1;6(8):1187-96. doi: 10.1016/j.dnarep.2007.03.017. Epub 2007 May 7. DNA Repair (Amst). 2007. PMID: 17482894 Free PMC article. Review.
-
Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.Ann N Y Acad Sci. 2005;1054:238-49. doi: 10.1196/annals.1345.030. Ann N Y Acad Sci. 2005. PMID: 16339671 Review.
Cited by
-
CAR-T cell therapy for hematological malignancies: History, status and promise.Heliyon. 2023 Nov 7;9(11):e21776. doi: 10.1016/j.heliyon.2023.e21776. eCollection 2023 Nov. Heliyon. 2023. PMID: 38027932 Free PMC article. Review.
-
CCAAT/enhancer-binding protein beta inhibits proliferation in monocytic cells by affecting the retinoblastoma protein/E2F/cyclin E pathway but is not directly required for macrophage morphology.J Biol Chem. 2011 Jul 1;286(26):22716-29. doi: 10.1074/jbc.M110.152538. Epub 2011 May 10. J Biol Chem. 2011. PMID: 21558273 Free PMC article.
-
Partially corrected X-linked severe combined immunodeficiency: long-term problems and treatment options.Immunol Res. 2009;43(1-3):223-42. doi: 10.1007/s12026-008-8073-6. Immunol Res. 2009. PMID: 18979075 Review.
-
Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.Gene Ther. 2017 May;24(5):298-307. doi: 10.1038/gt.2017.20. Epub 2017 Apr 20. Gene Ther. 2017. PMID: 28346436
-
Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice.Mol Ther. 2015 May;23(5):835-844. doi: 10.1038/mt.2015.16. Epub 2015 Feb 6. Mol Ther. 2015. PMID: 25655314 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials